Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.
Arrowhead Pharmaceuticals and Horizon Therapeutics announced a research and development collaboration to advance an RNA interference (RNAi) therapeutic for uncontrolled gout.
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
A new campaign from Horizon Therapeutics called Down and Out Kidney sheds light on the prevalence and impact of gout in chronic kidney disease, and aims to facilitate an important conversation with nephrologists – kidney specialists – particularly during National Kidney Month (March).
The U.S. FDA approved Ironwood Pharmaceuticals Inc.’s Duzallo as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.